The Role of biomarkers in valvular heart disease: Focus on natriuretic peptides

Canadian Journal of Cardiology

Volumn 30, Issue 9, 2014, Pages 1027-1034

  Bergler Klein, Jutta ^a   Gyöngyösi, Mariann ^a   Maurer, Gerald ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; COLLAGEN; ENDOTHELIN; MATRIX METALLOPROTEINASE; VON WILLEBRAND FACTOR;

AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; EXERCISE TEST; HEART FAILURE; HEART LEFT VENTRICLE; HUMAN; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; MITRAL VALVE STENOSIS; MORTALITY; PULMONARY HYPERTENSION; REFERENCE VALUE; REVIEW; TREATMENT OUTCOME; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

AGE FACTORS; AORTIC VALVE INSUFFICIENCY; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; FEMALE; HEART VALVE DISEASES; HUMANS; HYPERTENSION, PULMONARY; MALE; MITRAL VALVE INSUFFICIENCY; MITRAL VALVE STENOSIS; NATRIURETIC PEPTIDE, BRAIN; SEX FACTORS; TRICUSPID VALVE INSUFFICIENCY;

EID: 84906244666     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.07.014     Document Type: Review

References (70)

1. Steadman C.D., Ray S., Ng L.L., McCann G.P. Natriuretic peptides in common valvular heart disease. JAm Coll Cardiol 2010, 55:2034-2048.
2. Bhattacharyya S., Hayward C., Pepper J., Senior R. Risk stratification in asymptomatic severe aortic stenosis: a critical appraisal. Eur Heart J 2012, 33:2377-2387.
3. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. NEngl J Med 2002, 347:161-167.
4. Stanek B., Frey B., Hulsmann M., et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. JAm Coll Cardiol 2001, 38:436-442.
5. Iwanaga Y., Nishi I., Furuichi S., et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. JAm Coll Cardiol 2006, 47:742-748.
6. Vanderheyden M., Goethals M., Verstreken S., et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. JAm Coll Cardiol 2004, 44:2349-2354.
7. Kragelund C., Grønning B., Køber L., Hildebrandt P., Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. NEngl J Med 2005, 352:666-675.
8. Cimadevilla C., Cueff C., Hekimian G., et al. Prognostic value of B-type natriuretic peptide in elderly patients with aortic valve stenosis: the COFRASA-GENERAC study. Heart 2013, 99:461-467.
9. Vahanian A., Alfieri O., Andreotti F., et al. Guidelines on the management of valvular heart disease. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC). Eur Heart J 2012, 33:2451-2496.
10. Gerber I.L., Stewart R.A., Legget M.E., et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003, 107:1884-1890.
11. Weber M., Arnold R., Rau M., et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 2005, 26:1023-1030.
12. Bergler-Klein J., Klaar U., Heger M., et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004, 109:2302-2308.
13. Lim P., Monin J.L., Monchi M., et al. Predictors of outcome in severe aortic stenosis with normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J 2004, 25:2048-2053.
14. Weber M., Hausen M., Arnold R., et al. Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart 2006, 92:1639-1644.
15. Bergler-Klein J. Natriuretic peptides in the management of aortic stenosis. Curr Cardiol Rep 2009, 11:85-93.
16. Gerber I.L., Legget M.E., West T.M., Richards A.M., Stewart R.A. Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol 2005, 95:898-901.
17. Bergler-Klein J., Mundigler G., Pibarot P., et al. B-type natriuretic peptide in low-flow, low-gradient aortic stenosis: relationship to hemodynamics and clinical outcome: results from the multicenter Truly or Pseudo-Severe Aortic Stenosis (TOPAS) study. Circulation 2007, 115:2848-2855.
18. Bartko P.E., Heinze G., Graf S., et al. Two-dimensional strain for the assessment of left ventricular function in low flow-low gradient aortic stenosis, relationship to hemodynamics, and outcome: a substudy of the multicenter TOPAS study. Circ Cardiovasc Imaging 2013, 6:268-276.
19. Clavel M.A., Webb J.G., Rodés-Cabau J., et al. Comparison between transcatheter and surgical prosthetic valve implantation in patients with severe aortic stenosis and reduced left ventricular ejection fraction. Circulation 2010, 122:1928-1936.
20. Poulsen S.H., Sogaard P., Nielsen-Kudsk J.E., Egeblad H. Recovery of left ventricular systolic longitudinal strain after valve replacement in aortic stenosis and relation to natriuretic peptides. JAm Soc Echocardiogr 2007, 20:877-884.
21. Mannacio V., Antignano A., De Amicis V., et al. B-type natriuretic peptide as a biochemical marker of left ventricular diastolic function: assessment in asymptomatic patients 1 year after valve replacement for aortic stenosis. Interact Cardiovasc Thorac Surg 2013, 17:371-377.
22. Iwahashi N., Nakatani S., Umemura S., Kimura K., Kitakaze M. Usefulness of plasma B-type natriuretic peptide in the assessment of disease severity and prediction of outcome after aortic valve replacement in patients with severe aortic stenosis. JAm Soc Echocardiogr 2011, 24:984-991.
23. Pedrazzini G.B., Masson S., Latini R., et al. Comparison of brain natriuretic peptide plasma levels versus logistic EuroSCORE in predicting in-hospital and late postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosis. Am J Cardiol 2008, 102:749-754.
24. O'Sullivan CJ, Stortecky S, Heg D, etal. Impact of B-type natriuretic peptide on short-term clinical outcomes following transcatheter aortic valve implantation [epub ahead of print]. EuroIntervention 2014 Jan 17. pii: 20140117a-04.
25. López-Otero D., Trillo-Nouche R., Gude F., et al. Pro B-type natriuretic peptide plasma value: a new criterion for the prediction of short- and long-term outcomes after transcatheter aortic valve implantation. Int J Cardiol 2013, 168:1264-1268.
26. Scherzer S., Krenn L., Roth C., et al. The course of NT-ProBNP in real-life patients undergoing transfemoral aortic valve implantation. JAm Coll Cardiol 2014, ACC Scientific Sessions 2014, abstract.
27. Webb J., Rodés-Cabau J., Fremes S., et al. Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement. Can J Cardiol 2012, 28:520-528.
28. Nishimura R.A., Otto C.M., Bonow R.O., et al. 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129:e521-e643.
29. Lancellotti P., Donal E., Magne J., et al. Impact of global left ventricular afterload on left ventricular function in asymptomatic severe aortic stenosis: a two-dimensional speckle-tracking study. Eur J Echocardiogr 2010, 11:537-543.
30. Magne J., Mahjoub H., Pierard L.A., et al. Prognostic importance of brain natriuretic peptide and left ventricular longitudinal function in asymptomatic degenerative mitral regurgitation. Heart 2012, 98:584-591.
31. Bergler-Klein J., Rosenhek R., Gabriel H., et al. Correlation of N terminal pro B-type natriuretic peptide and speckle tracking derived longitudinal strain in severe asymptomatic aortic stenosis. JAm Coll Cardiol 2010, 55. A87.
32. Rajani R., Rimington H., Chambers J. B-type natriuretic peptide and tissue Doppler for predicting symptoms on treadmill exercise in apparently asymptomatic aortic stenosis. JHeart Valve Dis 2009, 18:565-571.
33. Rajani R., Rimington H., Chambers J.B. Treadmill exercise in apparently asymptomatic patients with moderate or severe aortic stenosis: relationship between cardiac index and revealed symptoms. Heart 2010, 96:689-695.
34. Monin J.L., Lancellotti P., Monchi M., et al. Risk score for predicting outcome in patients with asymptomatic aortic stenosis. Circulation 2009, 120:69-75.
35. Dumesnil J.G., Pibarot P. Low-flow, low-gradient severe aortic stenosis in patients with normal ejection fraction. Curr Opin Cardiol 2013, 28:524-530.
36. Lancellotti P., Magne J., Donal E., et al. Clinical outcome in asymptomatic severe aortic stenosis: insights from the new proposed aortic stenosis grading classification. JAm Coll Cardiol 2012, 59:235-243.
37. Herrmann S., Störk S., Niemann M., et al. Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. JAm Coll Cardiol 2011, 58:402-412.
38. Clavel M.A., Malouf J., Michelena H.I., et al. B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival. JAm Coll Cardiol 2014, 63:2016-2025.
39. Weber M., Hausen M., Arnold R., et al. Diagnostic and prognostic value of N-terminal pro B-type natriuretic peptide (NT-proBNP) in patients with chronic aortic regurgitation. Int J Cardiol 2008, 127:321-327.
40. Pizarro R., Bazzino O.O., Oberti P.F., et al. Prospective validation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic patients with chronic severe aortic regurgitation. JAm Coll Cardiol 2011, 58:1705-1714.
41. Gabriel R.S., Kerr A.J., Sharma V., Zeng I.S., Stewart R.A. B-type natriuretic peptide and left ventricular dysfunction on exercise echocardiography in patients with chronic aortic regurgitation. Heart 2008, 94:897-902.
42. Gerber I.L., Stewart R.A., Franch J.K., et al. Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation. Am J Cardiol 2003, 92:755-758.
43. Suri R.M., Vanoverschelde J.L., Grigioni F., et al. Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets. JAMA 2013, 310:609-616.
44. Sutton T.M., Stewart R.A., Gerber I.L., et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. JAm Coll Cardiol 2003, 41:2280-2287.
45. Detaint D., Messika-Zeitoun D., Avierinos J.F., et al. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 2005, 111:2391-2397.
46. Shimamoto K., Kusumoto M., Sakai R., et al. Usefulness of the brain natriuretic peptide to atrial natriuretic peptide ratio in determining the severity of mitral regurgitation. Can J Cardiol 2007, 23:295-300.
47. Potocki M., Mair J., Weber M., et al. Relation of N-terminal pro-B-type natriuretic peptide to symptoms, severity, and left ventricular remodeling in patients with organic mitral regurgitation. Am J Cardiol 2009, 104:559-564.
48. Klaar U., Gabriel H., Bergler-Klein J., et al. Prognostic value of serial B-type natriuretic peptide measurement in asymptomatic organic mitral regurgitation. Eur J Heart Fail 2011, 13:163-169.
49. Pizarro R., Bazzino O.O., Oberti P.F., et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. JAm Coll Cardiol 2009, 54:1099-1106.
50. Magne J., Mahjoub H., Pibarot P., et al. Prognostic importance of exercise brain natriuretic peptide in asymptomatic degenerative mitral regurgitation. Eur J Heart Fail 2012, 14:1293-1302.
51. Magne J., Mahjoub H., Dulgheru R., et al. Left ventricular contractile reserve in asymptomatic primary mitral regurgitation. Eur Heart J 2014, 35:1608-1616.
52. Kerr A.J., Raffel O.C., Whalley G.A., et al. Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation. Eur Heart J 2008, 29:363-370.
53. Hwang I.C., Kim Y.J., Kim K.H., et al. Prognostic value of B-type natriuretic peptide in patients with chronic mitral regurgitation undergoing surgery: mid-term follow-up results. Eur J Cardiothorac Surg 2013, 43:e1-e6.
54. Hwang I.C., Kim D.H., Kim Y.J., et al. Change of B-type natriuretic peptide after surgery and its association with rhythm status in patients with chronic severe mitral regurgitation. Can J Cardiol 2013, 29:704-711.
55. Taramasso M, Maisano F, Latib A, etal. Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation [Epub ahead of print]. EuroIntervention 2014 Jan 28. pii: 20130914-04.
56. Neuss M., Schau T., Schoepp M., et al. Patient selection criteria and midterm clinical outcome for MitraClip therapy in patients with severe mitral regur- gitation and severe congestive heart failure. Eur J Heart Fail 2013, 15:786-795.
57. Eryol N.K., Dogan A., Ozdogru I., et al. The relationship between the level of plasma B-type natriuretic peptide and mitral stenosis. Int J Cardiovasc Imaging 2007, 23:569-574.
58. Sharma V., Stewart R.A., Zeng I., Raffel C., Kerr A.J. Comparison of atrial and brain natriuretic peptide for the assessment of mitral stenosis. Heart Lung Circ 2011, 20:517-524.
59. Yoon C.H., Zo J.H., Kim Y.J., et al. B-type natriuretic peptide in isolated severe tricuspid regurgitation: determinants and impact on outcome. JCardiovasc Ultrasound 2010, 18:139-145.
60. Neuhold S., Huelsmann M., Pernicka E., et al. Impact of tricuspid regurgitation on survival in patients with chronic heart failure: unexpected findings of a long-term observational study. Eur Heart J 2013, 34:844-852.
61. Lancellotti P., Magne J. Tricuspid valve regurgitation in patients with heart failure: does it matter?. Eur Heart J 2013, 34:799-801.
62. Villafañe J., Feinstein J.A., Jenkins K.J., et al. Hot topics in tetralogy of Fallot. JAm Coll Cardiol 2013, 62:2155-2166.
63. Mahadavan G., Nguyen T.H., Horowitz J.D. Brain natriuretic peptide: a biomarker for all cardiac disease?. Curr Opin Cardiol 2014, 29:160-166.
64. Røsjø H., Andreassen J., Edvardsen T., Omland T. Prognostic usefulness of circulating high-sensitivity troponin T in aortic stenosis and relation to echocardiographic indexes of cardiac function and anatomy. Am J Cardiol 2011, 108:88-91.
65. Bergler-Klein J., Klaar U., Heger M., et al. Big endothelin-1 is not a predictor in aortic stenosis, but is related to arterial blood pressure. Int J Cardiol 2006, 113:174-180.
66. Raffa G.M., Jackson V., Liska J., et al. Endothelin-1 and brain natriuretic peptide plasma levels decrease after aortic surgery. JHeart Valve Dis 2010, 19:724-730.
67. Blackshear J.L., Wysokinska E.M., Safford R.E., et al. Indexes of von Willebrand factor as biomarkers of aortic stenosis severity (from the Biomarkers of Aortic Stenosis Severity [BASS] study). Am J Cardiol 2013, 111:374-381.
68. Steinlechner B., Zeidler P., Base E., et al. Patients with severe aortic valve stenosis and impaired platelet function benefit from preoperative desmopressin infusion. Ann Thorac Surg 2011, 91:1420-1426.
69. Sainger R., Grau J.B., Branchetti E., et al. Comparison of transesophageal echocardiographic analysis and circulating biomarker expression profile in calcific aortic valve disease. JHeart Valve Dis 2013, 22:156-165.
70. Park J.Y., Ryu S.K., Choi J.W., et al. Association of inflammation, myocardial fibrosis, and cardiac remodeling in patients with mild aortic stenosis as assessed by biomarkers and echocardiography. Clin Exp Pharmacol Physiol 2014, 41:185-191.